Anatomic and functional imaging in the manangement of lymphoma

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 51, Issue 3, 2007, Pages 251-259

  Al Nahhas, A ^a   Win, Z ^a   Al Sayed, Y ^a   Khan, S ^a   Singh, A ^a   Rubello, Domenico ^b   Gishen, P ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b Ospedale S Maria della Misericordia   (Italy)

Author keywords

Emision computed; Fluorodeoxyglucose F18; Hodgkin disease; Lymphoma, non hodgkin; Neoplasm staging; Tomography; Treatment, outcome

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CONTRAST MEDIUM; DACARBAZINE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GALLIUM 67; GALLIUM CITRATE GA 67; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; VINBLASTINE;

BONE MARROW METASTASIS; CANCER GRADING; CANCER RELAPSE; CANCER STAGING; CENTRAL NERVOUS SYSTEM METASTASIS; CHILDHOOD CANCER; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG UPTAKE; EVIDENCE BASED MEDICINE; HODGKIN DISEASE; HUMAN; IMAGE QUALITY; LAPAROTOMY; LYMPH NODE METASTASIS; LYMPHANGIOGRAPHY; LYMPHOMA; MINIMAL RESIDUAL DISEASE; MOLECULAR IMAGING; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

DIAGNOSTIC IMAGING; HUMANS; LYMPHOMA; MOLECULAR PROBE TECHNIQUES; NEOPLASM STAGING;

EID: 34547515717     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Swerdlow AJ. Epidemiology of Hodgkin's disease and non-Hodgkin's lymphoma. E J Nucl Med Mol Imaging 2003;30 Suppl 1:S3-12.
2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
3. Jaffe ES, Harris NL, Stien H, Vardiman JW, editors. World Health Organization Classification of tumours. Pathology and genetics of tumours of haematopoeitic and lymphoid tissue. Lyon: World Health Organization; 2001.
4. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971;31:1860-6.
5. Kreel L. The EMI whole body scanner in the demonstration of lymph node enlargement. Clin Radiol 1976;27:421-9.
6. Schaner EG, Head GL, Doppman JL, Young RC. Computed tomography in the diagnosis, staging and management of abdominal lymphoma. J Comput Assist Tomogr 1977; 1: 176-80.
7. 67Ga citrate. J Nucl Med 1969;10:103-5.
8. Iosilevsky G, Front D, Bettman L, Hardoff R, Ben-Arieh Y. Uptake of gallium-67 citrate and [2-3H]deoxyglucose in tumour model, following chemotherapy and radiotherapy. J Nucl Med 1985;26: 278-82.
9. McLaughlin AF Magee MA, Greenough R, Allman KC, Southee AE, Meikle SR et al. Current role of gallium scanning in the management of lymphoma. Eur J Nucl Med 1990;16:755-71.
10. Fox K, Silfen D, Alavi A. Application of gallium-67 scintigraphy in the management of patients with malignant lymphoma. J Nucl Med 1991;32:2299-305.
11. Hoffer P. Gallium: mechanisms. J Nucl Med 1980;21:282-5.
12. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
13. Schiepers C, Filmont JE, Czernin J. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S82-8.
14. Rodriguez M, Rehn S, Ahlstrom H, Sundstrom C, Glimelius B. Predicting malignancy grade with PET in Non-Hodgkin's lymphoma. J Nucl Med 1995;36:1790-6.
15. Lapela M, Leskinen S, Minn HR, Lindholm P, Klemi FJ, Soderstrom KO et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 1995;86:3522-7.
16. Okada J, Yoshikawa K, Itami M, Imaseki K, Uno K, Itami J et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 1992;33:325-9.
17. Okada J, Oonishi H, Yoshikawa K, Itami J, Uno K, Imaseki K et al. FDG-PET for predicting the prognosis of malignant lymphoma. Ann Nucl Med 1994;8:187-91.
18. 18F-fluoro-2-deoxygluose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma. Oncol Rep 2002;9: 321-5.
19. Wirth A, Seymour JF, Hicks RJ, Ware R, Fisher R, Prince M et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 2002; 112:262-8.
20. Even-Sapir E, Israel O. Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma. Eur J Nucl Med Mol Imaging 2003;30 Suppl I:S65-81.
21. Barrington SF, O'Doherty MJ. Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S117-27.
22. Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994;190:111-6.
23. 18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol 2006;17:780-4.
24. Jerusalem GH, Beguin YP. Positron emission tomography in non-Hodgkin's lymphoma (NHL): relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL. Clin Lymphoma 2002;3:56-61.
25. Israel O, Keidar Z, Bar-Shalom R. Positron emission tomography in the evaluation of lymphoma. Semin Nucl Med 2004;34:166-79.
26. Hicks RJ, Mac Manus MP, Seymour JF. Initial staging of lymphoma with positron emission tomography and computed tomography. Semin Nucl Med 2005;35:165-75.
27. van den Brekel MW, Stel HV, Castelijns JA, Nauta JJ, van der Waal I, Valk J et al. Cervical lymph node metastasis: assessment of radiologic criteria. Radiology 1990;177:379-84.
28. Glazer GM, Gross BH, Quint LE, Francis IR, Bookstein FL, Orringer MB. Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping. Am J Roentgenol 1985;144:261-5.
29. Dorfman RE, Alpern MB, Gross BH, Sandler MA. Upper abdominal lymph nodes: criteria for normal size determined with CT. Radiology 1991;180:319-22.
30. Pombo F, Rodriguez E, Caruncho MV, Villalva C, Crespo C. CT attenuation values and enhancing characteristics of thoracoabdominal lymphomatous adenopathies. J Comput Assist Tomogr 1994;18:59-62.
31. Apter S, Avigdor A, Gayer G, Portnoy O, Zissin R, Hertz M. Calcification in lymphoma occurring before therapy: CT features and clinical correlation. Am J Roentgenol 2002; 178:935-8.
32. Hopper KD, Diehl LF, Cole BA, Lynch JC, Meilstrup, JW, McCauslin MA. The significance of necrotic mediastinal lymph nodes on CT in patients with newly diagnosed Hodgkin disease. Am J Roentgenol 1990;155:267-70.
33. Gallagher CJ, White FE, Tucker AK, Fry IK, Malpas JS, Lister TA. The role of computed tomography in the detection of intrathoracic lymphoma. Br J Cancer 1984;49:621-9.
34. Dooms GC, Hricak H, Crooks LE, Higgins CB. Magnetic resonance imaging of the lymph nodes: comparison with CT Radiology 1984;153:719-28.
35. Lee JK, Heiken JP, Ling D, Glazer HS, Balfe DM, Levitt RG et al. Magnetic resonance imaging of abdominal and pelvic lymphadenopathy. Radiology 1984;153:181-8.
36. Linden A, Zankovich R, Theissen P, Diehl V, Schicha H. Malignant lymphoma: bone marrow imaging versus biopsy. Radiology 1989;173:335-9.
37. Kim JH, Beets GL, Kim MJ, Kessels AG, Beets-Tan RG. High-resolution MR imaging for nodal staging in rectal cancer: are there any criteria in addition to the size? Eur J Radiol 2004;52:78-83.
38. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004;231:305-32.
39. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Kotzerke J, Merkle E et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997;203:795-800.
40. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Merkle E, Frickhofen N et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998;206:475-81.
41. Buchmann I, Reinhardt M, Elsner K, Bunjes D, Altehoefer C, Finke J et al. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 2001;91:889-99.
42. Carr R, Barrington SF, Madan B, O'Doherty MJ, Saunders CA, van der Walt J et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998;91:3340-6.
43. Partridge S, Timothy A, O'Doherty MJ, Hain SF, Rankin S, Mikhaeel G. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Ann Oncol 2000;11:1273-9.
44. Munker R, Glass J, Griffeth LK, Sattar T, Zamani R, Heldmann M et al. Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease. Ann Oncol 2004;15:1699-704.
45. Naumann R, Beuthien-Baumann B, Reiss A, Schulze J, Hanel A, Bredow J et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer 2004;90:620-5.
46. Jerusalem G, Hustinx R, Beguin Y, Fillet G. Positron emission tomography imaging for lymphoma. Curr Opin Oncol 2005;17:441-5.
47. 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 2005; 104:10 6-74.
48. Russell KJ, Hoppe RT. Response of mediastinal Hodgkin's disease to radiotherapy: rate of tumor regression not predictive of outcome. Int J Radiat Oncol Biol Phys 1989; 16:201-4.
49. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002;13:1356-63.
50. 67Ga scintigraphy. Radiology 2000;214:253-7.
51. Hill M, Cunningham D, MacVicar D, Roldan A, Husband J, McCready R et al. Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma. J Clin Oncol 1993;11:2273-8.
52. Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN. 18-FDG PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's lymphoma-comparison with CT. Leuk Lymphoma 2000;39:543-53.
53. Mikhaeel NG, Timothy AR, Hain SF, O'Dohetry MJ. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol 2000;11 Suppl 1:147-50.
54. Kostakoglu L, Goldsmith SJ. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears? Eur J Nucl Med 2000;27:1564-78.
55. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002;43:1018-27.
56. Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006;91:475-81.
57. Eich HT, Staar S, Gossmann A, Engert A, Franklin J, Sieber M et al. German Hodgkin Lymphoma Study Group. The HD12 panel of the German Hodgkin Lymphoma Study Group (GHSG): a quality assurance program based on a multidisciplinary panel reviewing all patients'imaging. Am J Clin Oncol 2004;27:279-84.
58. Nyman RS, Rehn SM, Glimelius BL, Hagberg BE, Hemmingsson AL, Sundstrom CJ. Residual mediastinal masses in Hodgkin disease: prediction of size with MR imaging. Radiology 1989;170:435-40.
59. 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma. Oncol Rep 2001;8:1393-9.
60. 18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results. Oncol Rep 2005;14:1209-14.
61. 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med 2003;44:1225-31.
62. Juweid ME, Wiseman GA, Menda Y, Vose J, Links B, Graham MM. FDG-PET in the prediction of progression free survival at 1-year of patients with aggressive non-Hodgkin's lymphoma following antracycline based first line chemotherapy. Eur J Nucl Med 2002;29 Suppl 1:S264.
63. Zinzani PL, Fand S, Battista G, Tani M, Castellucci P, Stefoni V et al. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer 2004;91:850-4.
64. Rahmouni A, Divine M, Lepage E, Jazaerli N, Belhadj K, Gaulard P et al. Mediastinal lymphoma: quantitative changes in gadolinium enhancement at MR imaging after treatment. Radiology 2001;219:621-8.
65. Rehn S, Nyman R, Glimelius BL, Hagberg HE, Sundstrom JC. Non-Hodgkin lymphoma: predicting prognostic grade with MR imaging. Radiology 1990;176:249-53.
66. Spaepen K, Stroobants S, Dupont P, Thomas J, Vandenberghe P, Balzarini J et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001;115:272-8.
67. 18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001;19:414-9.
68. 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999;94:429-33.
69. 18F-FDG PET in children with lymphomas. Eur J Nucl Med Mol Imaging 2005;32:31-8.
70. Montravers F, McNamara D, Landman-Parker J, Grahek D, Kerrou K, Younsi N et al. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management. Eur J Nucl Med Mol Imaging 2002;29:1155-65.
71. 18F-FDG-avid sites mimicking active disease in paediatric Hodgkin's. Pediatr Radiol 2005;35:141-54.
72. Hoh CK, Glaspy J, Rosen P, Dahlborn M, Lee SJ, Kunkel L et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997;38:343-8.
73. Klose T, Leidl R, Buchmann I, Brambs HJ, Reske SN. Primary staging of lymphomas: cost-effectiveness of FDG-PET versus computed tomography. Eur J Nucl Med 2000;27:1457-64.
74. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology 2006;238:405-22.
75. Brianzoni E, Rossi G, Ancidei S, Berbellini A, Capoccetti F, Cidda C et al. Radiotherapy planning: PET/CT scanner performances in the definition of gross tumour volume and clinical target volume. Eur J Nucl Med Mol Imaging 2005;32:1392-9.
76. 18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol 2004;6:411-6.
77. Tatsumi M, Cohade C, Nakamoto Y, Fishman EK, Wahl RL. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. Radiology 2005;237:1038-45.
78. Raanani P, Shasha Y, Perry C, Metser U, Naparstek E, Apter S et al. Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? Ann Oncol 2006;17:117-22.